Recently, the truncated sst5 variant, sst5TMD4, related to the abnormal responses to SST analogs in pituitary tumors has been identified in poorly differentiated human breast cancers, where it correlates and interacts with sst2 altering its signaling and affecting tumor pathophysiology, while it is absent in normal mammary gland [184]. The gene discussed is CORT; the disease is neoplasm.